Analytical Methods for Xanomeline and Trospium Chloride: A Review and Future Outlook

An innovative treatment for schizophrenia has been approved by the U.S. Food and Drug Administration, which combines the muscarinic antagonist trospium chloride with the muscarinic agonist xanomeline. It is a new therapeutic option that attacks the fundamental neurobiology of schizophrenia in a fresh way. A negligible portion of people worldwide suffer from schizophrenia, a persistent and crippling mental illness. The disorder has a major influence on everyday functioning and quality of life. Antipsychotic drugs have significant adverse effects, although they are often beneficial. Furthermore, they frequently have minimal effects on the negative and cognitive symptoms of schizophrenia. In the absence of the typical adverse effects of dopamine-targeting antipsychotics, combination therapy with xanomeline and trospium chloride has shown notable effectiveness in lowering both positive and negative symptoms of schizophrenia. A careful review of the literature revealed that no analytical method for estimation has been developed for this combination of medications. The current article examines the analytical techniques that are available for each drug separately, which may help researchers create an analytical technique that takes into account the importance of each drug in combination.